...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Nonhepatic cancer in liver cirrhosis: a retrospective study of prevalence, complication rate after specific oncological treatment, follow-up and prognostic predictors of outcome in 354 patients with cirrhosis.
【24h】

Nonhepatic cancer in liver cirrhosis: a retrospective study of prevalence, complication rate after specific oncological treatment, follow-up and prognostic predictors of outcome in 354 patients with cirrhosis.

机译：肝硬化中非肝癌的回顾性研究：354例肝硬化患者的患病率，特定肿瘤治疗后的并发症发生率，随访结果和预后指标。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: Nonhepatic cancer risk of cirrhotic patients seems to be increased. Major surgery and chemotherapy in cirrhosis are associated with increased mortality and morbidity, which limits treatment. AIM: The aims of this study were analysis of (a) prevalence, (b) outcome after treatment, (c) of survival rate and (d) predictors of survival in a cirrhotic population. PATIENTS AND METHODS: The study population was assembled retrospectively from a database of hospitalized patients (n=354). The Kaplan-Meier method was used to calculate the survival rate, and Cox regression analysis was performed to identify prognostic parameters. RESULTS: Altogether, 84 neoplasms in 70 patients were observed. A total of 54 were nonhepatic (15.3%) mainly colorectal carcinoma, prostate cancer and tobacco-related neoplasms. TNM stage was the best prognostic parameter (p<0.0001). Low bilirubin (p=0.01), normal albumin (p=0.005) and absence of ascites (p<0.0001) were also related significantly to longer survival. The rate of postinterventional death after specific treatment was high. A proportion of patients received no specific therapy due to reduced physical performance, even in cases of limited disease. CONCLUSION: Our data confirm the increased risk of cirrhotic patients for developing nonhepatic cancer. Advanced TNM stage was associated with reduced long-term survival. Scoring systems, such as Child's classification and Model of Elevated Liver Disease (MELD) score, were suitable parameters to predict mortality. Oncological management in patients with cirrhosis must be on an individual basis, independent from TNM classification.
机译：背景：肝硬化患者的非肝癌风险似乎增加。肝硬化的大手术和化学疗法会增加死亡率和发病率，从而限制了治疗。目的：本研究的目的是分析（a）肝硬化人群的患病率，（b）治疗后的结局，（c）生存率和（d）生存预测因子。患者与方法：研究对象是从住院患者的数据库中回顾性收集的（n = 354）。使用Kaplan-Meier方法计算生存率，并进行Cox回归分析以鉴定预后参数。结果：共观察到70例患者的84例肿瘤。共有54例为非肝癌（占15.3％），主要是大肠癌，前列腺癌和与烟草有关的肿瘤。 TNM分期是最好的预后参数（p <0.0001）。低胆红素（p = 0.01），正常白蛋白（p = 0.005）和无腹水（p <0.0001）也与更长的生存期显着相关。特殊治疗后介入治疗后的死亡率很高。由于身体机能下降，即使在疾病有限的情况下，也有一部分患者没有接受特殊治疗。结论：我们的数据证实了肝硬化患者发展为非肝癌的风险增加。晚期TNM分期与长期生存期降低有关。计分系统，例如儿童分类和肝病高模型（MELD）评分，是预测死亡率的合适参数。肝硬化患者的肿瘤学治疗必须基于个体，与TNM分类无关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号